FIELD: medicine.
SUBSTANCE: invention relates to peroral introduction to patients of pharmaceutical composition, containing a) agent for peroral delivery, which represents disodium salt of N-(5-chlorsalicyloyl)-8-aminocaprylic acid or hydrate, or solvate of said disodium salt; and b) approximately 0.1-2.5 mg of calcitonin; into which ratio of agent for peroral delivery, expressed as respective amount of free acid, to amount of calcitonin is within the limits approximately from 10 to approximately 250:1 wt, where peroral introduction takes place approximately 5-30 minutes before meals.
EFFECT: improvement of calcitonin introduction.
6 cl, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CALCITONIN USED AT OSTEOARTHRITIS | 2004 |
|
RU2368390C2 |
| APPLICATION OF CALCITONIN FOR TREATING RHEUMATOID ARTHRITIS | 2006 |
|
RU2453330C2 |
| PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2469709C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING HGH FOR ORAL ADMINISTRATION | 2007 |
|
RU2493868C2 |
| 5-CNAC AS AGENT FOR ORAL DELIVERY OF PARATHYROID HORMONE FRAGMENTS | 2002 |
|
RU2322256C2 |
| ORAL ADMINISTRATION OF PARATHYROID HORMONE AND CALCITONIN | 2002 |
|
RU2300392C2 |
| CRYSTALLINE FORMS OF DISODIUM SALT OF N-(5-CHLOROSALICILOUL-)-8-AMINOCAPRYLIC ACID | 2006 |
|
RU2507196C2 |
| PHARMACEUTICAL COMPOSITIONS FOR PERORAL INTAKE OF PHARMACOLOGICAL ACTIVE SUBSTANCES | 2001 |
|
RU2287999C2 |
| PEPTIDE ANALOGS FOR TREATMENT OF DISEASES AND DISORDERS | 2012 |
|
RU2616511C2 |
| MIMETIC CALCITONIN FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2689551C1 |
